Loading...
Loading...
IMNN| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 198.3K |
| Gross Profit | -198.3K |
| Operating Expense | 3,904.1K |
| Operating I/L | -3,904.1K |
| Other Income/Expense | 427.5K |
| Interest Income | 264.3K |
| Pretax | -3,476.6K |
| Income Tax Expense | 237.9K |
| Net Income/Loss | -3,476.6K |
Imunon, Inc. is a clinical stage biotechnology company specializing in DNA-based immunotherapies, vaccines, and directed chemotherapies. Their product pipeline includes GEN-1, a DNA-based immunotherapy for localized ovarian cancer treatment, and ThermoDox, a heat-activated liposomal encapsulation of doxorubicin for various cancer indications. Additionally, the company has two feasibility stage platform technologies for developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Imunon, Inc. generates revenue through the development and commercialization of these innovative treatments for cancer and other diseases.
